Royal Bank Of Canada Increases Bio-Rad Laboratories (NYSE:BIO) Price Target to $370.00

Bio-Rad Laboratories (NYSE:BIO) had its price target boosted by analysts at Royal Bank Of Canada from $320.00 to $370.00 in a research report issued to clients and investors on Wednesday,Benzinga reports. The firm presently has an “outperform” rating on the medical research company’s stock. Royal Bank Of Canada’s target price would suggest a potential upside of 8.39% from the stock’s previous close.

Other equities research analysts have also issued reports about the company. Wells Fargo & Company lifted their price target on Bio-Rad Laboratories from $310.00 to $330.00 and gave the company an “equal weight” rating in a research report on Wednesday. Zacks Research downgraded shares of Bio-Rad Laboratories from a “hold” rating to a “strong sell” rating in a research report on Monday, July 13th. Citigroup cut shares of Bio-Rad Laboratories from a “buy” rating to a “neutral” rating and lowered their price target for the company from $375.00 to $300.00 in a research report on Tuesday, April 7th. Finally, Weiss Ratings restated a “sell (d)” rating on shares of Bio-Rad Laboratories in a report on Monday. One analyst has rated the stock with a Buy rating, two have given a Hold rating and two have given a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Reduce” and an average target price of $333.33.

Bio-Rad Laboratories Trading Up 2.5%

Shares of NYSE BIO traded up $8.48 during midday trading on Wednesday, hitting $341.36. 183,752 shares of the company traded hands, compared to its average volume of 328,296. Bio-Rad Laboratories has a 12-month low of $236.73 and a 12-month high of $352.63. The firm has a market cap of $9.13 billion, a P/E ratio of 56.45 and a beta of 1.06. The stock has a 50-day moving average price of $301.02 and a 200 day moving average price of $287.81. The company has a debt-to-equity ratio of 0.12, a quick ratio of 2.37 and a current ratio of 3.21.

Bio-Rad Laboratories (NYSE:BIO) last posted its quarterly earnings data on Tuesday, August 4th. The medical research company reported $2.62 earnings per share for the quarter, beating the consensus estimate of $1.75 by $0.87. Bio-Rad Laboratories had a return on equity of 3.56% and a net margin of 6.52%.The business had revenue of $651.00 million for the quarter, compared to analysts’ expectations of $623.99 million. During the same period in the previous year, the firm posted $2.61 EPS. The business’s revenue was down .1% on a year-over-year basis. As a group, analysts expect that Bio-Rad Laboratories will post 9.14 earnings per share for the current year.

Institutional Trading of Bio-Rad Laboratories

Several hedge funds have recently modified their holdings of BIO. First Eagle Investment Management LLC increased its holdings in shares of Bio-Rad Laboratories by 2.0% in the 4th quarter. First Eagle Investment Management LLC now owns 2,570,473 shares of the medical research company’s stock worth $778,828,000 after buying an additional 50,154 shares during the last quarter. Dimensional Fund Advisors LP boosted its stake in Bio-Rad Laboratories by 1.1% during the first quarter. Dimensional Fund Advisors LP now owns 1,089,323 shares of the medical research company’s stock worth $303,637,000 after buying an additional 12,251 shares during the period. Capital Research Global Investors raised its stake in shares of Bio-Rad Laboratories by 18.2% in the fourth quarter. Capital Research Global Investors now owns 494,472 shares of the medical research company’s stock valued at $149,820,000 after acquiring an additional 76,117 shares during the period. Bank of America Corp DE boosted its stake in shares of Bio-Rad Laboratories by 1.7% during the 3rd quarter. Bank of America Corp DE now owns 459,887 shares of the medical research company’s stock worth $128,948,000 after purchasing an additional 7,754 shares during the period. Finally, Massachusetts Financial Services Co. MA grew its holdings in Bio-Rad Laboratories by 4,534.4% during the 4th quarter. Massachusetts Financial Services Co. MA now owns 399,207 shares of the medical research company’s stock valued at $120,956,000 after purchasing an additional 390,593 shares during the last quarter. 65.24% of the stock is owned by hedge funds and other institutional investors.

Bio-Rad Laboratories News Summary

Here are the key news stories impacting Bio-Rad Laboratories this week:

• Positive Sentiment: Quarterly earnings exceeded expectations. Bio-Rad reported adjusted earnings of $2.62 per share, well above the $1.75 consensus estimate, while revenue of $651 million also surpassed expectations of approximately $624 million. Earnings were broadly stable year over year despite essentially flat revenue. Bio-Rad Laboratories quarterly earnings results
• Positive Sentiment: Higher price target provides some support. Wells Fargo raised its target for BIO from $310 to $330, reflecting improved expectations following the results, although the firm maintained an “equal weight” rating. Wells Fargo raises Bio-Rad price target
• Neutral Sentiment: Full-year outlook remains mixed. Bio-Rad forecast fiscal 2026 revenue of $2.5 billion to $2.6 billion, roughly in line with the $2.6 billion analyst consensus. The guidance does not indicate significant near-term revenue acceleration. Bio-Rad beats second-quarter earnings estimates
• Negative Sentiment: Cost-cutting plans create execution and growth concerns. The company plans to cut jobs and close facilities, signaling efforts to improve efficiency but also highlighting pressure on operations and demand. Bio-Rad Laboratories to cut jobs and close facilities
• Negative Sentiment: Valuation and analyst positioning may limit upside. Wells Fargo’s target remains below the recent trading level, and its equal-weight rating suggests the earnings beat may already be reflected in the stock price.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc is a global provider of life science research and clinical diagnostic products. The company operates through two primary business segments: Life Science and Clinical Diagnostics. Within the Life Science segment, Bio-Rad offers instruments, reagents and consumables for protein analysis, cell biology, gene expression and other molecular biology applications. The Clinical Diagnostics segment supplies quality control products, blood-typing reagents and instruments, and molecular diagnostic assays used in blood screening, infectious disease testing and routine clinical laboratories.

Founded in 1952 by David and Alice Schwartz and headquartered in Hercules, California, Bio-Rad has grown its footprint across the Americas, Europe, Asia-Pacific and other regions.